Jan 21st 2013 - Edison Investment Research today published a report on Neovacs entitled "Crohn’s Trials Are Still On". In summary, the report says:
Despite disappointing interim Phase II trial results in Crohn’s disease (CD) in June, recent final results from the same trial demonstrated an encouraging association between the TNFα-Kinoid induced antibody titres and clinical remission. These supportive results would appear to confirm the hypothesis that the original study design was flawed, which led to disappointing results. This, together with promising new Phase II data in rheumatoid arthritis (RA) at six months, supports the continued development of the TNFα-Kinoid in both CD and RA. The next step for the TNFα-Kinoid is a Phase IIb/III study. Neovacs is also developing an IFNα-Kinoid for lupus, which is ready to move into a Phase IIb study, pending a financing or partnership.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »